ANZUP 2017 Interviews - David Quinn

from Talking Urology Podcast · host Talking Urology

David Quinn discusses the KEYNOTE-045 trial on the benefits of pembrolizumab in second line treatment of advanced bladder cancer

Episode metadata supplied by the publisher feed · Published Nov 29, 2017

Embed this episode

Attribution link and audio player

NOW PLAYING

ANZUP 2017 Interviews - David Quinn

0:00 16:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 16 minutes long.

This episode was published on November 29, 2017.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!